Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
about
Molecular biology of lung cancerAssociation of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.Epidermal growth factor receptor in non-small cell lung cancerEGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practiceClinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis.Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemImpact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasImaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Clinical potential of gene mutations in lung cancer.Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Tobacco Smoking and Lung Cancer: Perception-changing factsEmerging options for the management of non-small cell lung cancer.Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status.Lung cancer in women: an overview with special focus on Spanish women.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.Trends and Outcomes of Non-Small-Cell Lung Cancer in Omani Patients: Experience at a university hospital.Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans' Affairs Central Cancer Registry (VACCR) cohort analysis.
P2860
Q24606677-77EA92FD-8782-4701-9F2A-93F4D8950164Q27851860-310BF7FB-1883-44B5-BCEB-F33F32EB2F99Q28088636-B3B2A773-8CAF-4819-AB8D-3342EDAFA214Q30664830-86B4AF49-57D4-4412-B4B6-38C586269C7CQ31167585-93F25CE6-CEE5-49A9-A9D4-0C44196F1A43Q34000975-3E78766E-6D61-400E-833C-3ED1238FA098Q34608597-94CD74B1-5D02-40C5-A120-14AC571BB608Q35587238-816453F3-857B-4B9E-9485-73163AA20E78Q35775729-4E28229E-36E1-47D6-8201-27A24BA5937FQ36102892-21CEEE1D-CAFB-432A-915B-34E3F2880771Q36250691-01D2BF27-2841-4F9E-9275-B5BF74F304BBQ36316009-19EADAB9-4212-4077-B36B-CE38F23ABA01Q36761302-BD32BB4F-0056-4194-8EED-A58890D5BDBCQ36865033-8C5D4F81-25CE-42FE-9BDF-BFFA10040607Q36996220-6E62946B-FA9C-4BB7-B966-D15B487C2DE4Q37109569-F6A26715-2479-4A87-A840-1976694EB63DQ37269316-CCC2A7D8-307B-43FD-86E8-44A12704FD84Q37567804-8ED7B788-57AE-4D41-8BEA-8228C19F15DAQ38166318-9355740E-7861-4B0B-BA21-2675B6800BC7Q38682370-E9A1C649-E428-430A-99BF-873DD3CDF413Q39027385-3EE8C714-78E1-4C19-AAA2-52E843539FC8Q42340129-B5C536C7-1819-4BCB-9A0C-E2A1EC9EA9DDQ42877878-12E0E865-F9F2-444C-A18E-687F846CA2DAQ45307428-E03B5B0E-34EA-4AF1-97FF-91739B386BFE
P2860
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Driver mutations determine sur ...... IIIB/IV lung adenocarcinomas.
@ast
Driver mutations determine sur ...... IIIB/IV lung adenocarcinomas.
@en
type
label
Driver mutations determine sur ...... IIIB/IV lung adenocarcinomas.
@ast
Driver mutations determine sur ...... IIIB/IV lung adenocarcinomas.
@en
prefLabel
Driver mutations determine sur ...... IIIB/IV lung adenocarcinomas.
@ast
Driver mutations determine sur ...... IIIB/IV lung adenocarcinomas.
@en
P2093
P2860
P356
P1433
P1476
Driver mutations determine sur ...... IIIB/IV lung adenocarcinomas.
@en
P2093
Camelia S Sima
Daphne Ang
Gregory J Riely
Mark G Kris
Melissa L Johnson
Paul K Paik
Sandra P D'Angelo
Snjezana Dogan
Vincent A Miller
P2860
P304
P356
10.1002/CNCR.27637
P407
P50
P577
2012-05-17T00:00:00Z